21Schizm Horizontal

Mark Cuban Posterizes the Big Pharma With New Online Pharmacy Venture

Big Pharma cannot find its footing. After Mark Cuban and his lofty titled company post up for a major slam dunk. Cost Plus Drugs heralds itself as the forefront of cheaper, legitimate, and generic pharmaceuticals. Now, one may find themselves asking how this benefits the neurodivergent community. At a glance the most definite impact resonates from the prices. Cheap, cheaper, and sometimes cheapest paired with generic, brand name and sometimes substituted. Firstly, the objective, provide low cost drugs for a greedy capitalist saturated field. Secondly, the method, cutout the middleman and facilitate “cost-plus pricing” (“cost-plus pricing” is a term which will be clarified later). Finally, The ultimatum, manufacture wholesale and pharmacy distribution of drugs. In this article one intends in bridging the former exploits of pharmacy to Cuban’s modern approach.

Photo by Myriam Zilles on Unsplash

How did Big Pharma Get so Big?

In writing this article the assumption of greed on the part of some party seems evident or somewhat distinguishable. Furthermore, nowhere along the development of this field could anyone foresee humanity’s subversion to gross profit. First, one must explain the topic “cost-plus pricing.” It’s a pricing method where a fixed percentage is added on top of the cost it takes to produce one unit of a product (unit cost). However, prior to analyzing Cuban’s method. Perhaps one must indulge themselves in the history of Big Pharma.

Big Pharma Training Days

Although, Big Pharma arrived on the scene in the 1800’s with humble beginnings. Things eventually took a massive spiral as a collective of companies figuratively proclaimed their presence as the sole roster in the game. Initially, starting with the discovery of morphine, the toddling behemoth put forth its best foot with this staple drug in possession. Oddly enough, most of the early attempts found themselves on the shelves of apothecaries. With the boundless possibilities of pharmaceuticals for good one would find themselves with one question .The question in hand asks whether Big Pharma represents competition to psychiatry or a friendly alliance.

Big Pharma and Psychiatry, the Big Tradeoff

Simply put, psychiatry reserves no easy path. In grappling with mental illness one must consider a number of different types of treatment. All including psychotherapy, psychosocial treatment, and medications. While studies depict a favorable outlook on psychotherapy without medications. The actual field depends moreso on medications than anything else. Only, because Big Pharma has settled agency into the psychiatric sphere. Moreover, Big Pharma positions itself as a major offense in the field of psychiatry. With little to no competition, Big Pharma has projected its market on the field with what looks like a monopoly. When one mentions Big Pharma and its monopoly, one refers to the world’s largest publicly traded pharmaceutical companies. While this ranges from 10 to 20 separate companies, their desire remains the same in the face of psychiatry. Wager the stability and health of millions against the profit and greed of Big Pharma.

Government Lobby, a Team Player?

If one is going to be in the game then one must play for some team. This is self-evident. Now how this factors for the mentally bound and government lobbies beholds about a messy schematic. Firstly, shirts and skins, Big Pharma with the button-ups and psychiatry with the patches. The purpose of psychiatry remains to treat and prevent mental illness. This may include medications. The crux of the matter stems from whether the distributor intends to only make profit with little regard for the patient, otherwise known as Button-ups. On the other hand, those humble few who intend in pedestalling care above profit also known as the patches.

In the government lobbies, the trend of big players often tends to side with Button ups, under the guise of seemingly friendly slogans. Slogans such as, stop the stigma. These campaigns secretly benefit those who profit from a larger population of the mentally bound. Furthermore it seems that government lobbies do sport the button-ups as they feign toward stopping the stigma and covertly increasing gains.

Mark Cuban Cost Plus Drugs Vs Big Pharma

Critics express an excess of fear and failure on the part of Big Pharma. This emerges when one draws comparisons to Mark Cuban’s endeavor. His most declarative statement on the matter asserts that this may turn the pharmaceutical industry “upside down.” One believes that this forebodes well for all parties involved, except Big Pharma. The incorporations listing as a Public Benefit Corporation regards it as a champion or at least an advocate for the people. Meanwhile, Big Pharma elevates its prices in response and loses more and more customers. Mark Cuban’s incorporation proclaims a meager 15% markup of the manufacturer’s cost with a $3.00 pharmacist fee and $5.00 shipping or $15.00 expedited shipping.

Photo by Jon Tyson on Unsplash

Government Lobby Trades to Cuban?

Although critics contend that the United States government could save 3.6 billion by opting for Cuban’s approach. Prying the government from Big Pharma’s grasp evokes a much more burdensome task. Medicare spends 115 billion dollars per year on prescription drugs. Medicare represents a third of spending on prescription drugs. Additionally, Cuban’s approach represents a cornerstone in terms of stepping toward the next generation. Online pharmaceuticals definitely retain a place in the oncoming future. Cuban evidently rings true to his title as a Maverick. The government totes deep entrenchment with Big Pharma as a partnership with Cuban seems distant. Regardless, Cuban clasped the attention of multitudes of people, unless the government proves blind, perhaps the two may find themselves enthralled with each other.

Big Pharma
Photo by Andrew Krasilnikov on Unsplash

CostPlusDrugs vs. Big Pharma By 10

CostPlusDrugs now versus Big Pharma in 10 years represents the major competition. No matter who you pit them against, CostPlusDrugs emerges as the scrappier and edgier pick. They do not wield a comfortable lead like Big Pharma. But, that represents why Mark Cuban brandishes the Maverick title. Cuban’s company faces less of the challenges than early BigPharma and seemingly more growth potential.

Their advantage presents itself through the advent of easier and more seamless communication. Perhaps the most difficult challenge for CostPlusDrugs belies in the garnering of governmental interest. Without Medicare, nowhere else does it seem one can identify cheaper psych drugs. Also no where else grounds areas for psych meds without the purpose of making a major profit. Cuban’s company will do just what he promised. In upturning the pharmaceutical field Cuban the Maverick lines up for the slam. 21SCHIZM intends to bear witness to the dunk in oncoming years.

Leave a Reply

Your email address will not be published. Required fields are marked *

You’ll also like